The plan seeks to modernize the US biomedical data handling infrastructure, in order to to keep up with the explosive growth in information from genomics research.
The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.
Near-term, the firm is focused on its cost structure and growing its top line with a view to becoming profitable, according to its interim CEO.
The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The document is one of the early fruits of GA4GH Connect, a five-year initiative to better align the group's objectives with the key needs of the international genomic data community.
The institute expects to announce its strategic plan in October 2020 to commemorate the 30th anniversary of the launch of the Human Genome Project.
Called GA4GH Connect, it calls on the alliance's 500-plus members to develop new data sharing standards for use in major international genomic data initiatives.
Core elements of the new program include integrating genomic data into electronic medical records and the establishment of a national genome center.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.